24399428Pollack MH, Van Ameringen M, Simon NM, Worthington JW, Hoge EA, Keshaviah A, Stein MBThe American journal of psychiatryAnti-Anxiety Agents; Clonazepam; Cyclohexanols; Phobic Disorders; SertralineAdult; Double-Blind Method; Drug Administration Schedule; Drug Therapy, Combination; Female; Humans; Male; Middle Aged; Severity of Illness Index; Treatment Outcome; Venlafaxine HydrochlorideA double-blind randomized controlled trial of augmentation and switch strategies for refractory social anxiety disorder. Am J Psychiatry. 2014 Jan; 171(1):44-53.Am J Psychiatry2014-01-01T00:00:002014A double-blind randomized controlled trial of augmentation and switch strategies for refractory social anxiety disorder.Faculty Rankprns:fullNamefull nameprns:hasAuthorListauthor listprns:hasFacultyRankhas faculty rankprns:hasNetworkhas networkprns:hasPublicationVenuepublished inprns:hasSubjectAreaMajorTopicListhas major subject area listprns:hasSubjectAreaMinorTopicListhas minor subject area listprns:informationResourceReferenceinformation resource referenceprns:isPrimaryPositionis primary positionprns:latitudelatitudeprns:longitudelongitudeprns:mainImagephotoprns:maxWeightmaximum weightprns:medlineTAjournal title abbreviationprns:meshDescriptorUIMeSH DescriptorUIprns:meshSemanticGroupNameMeSH semantic group nameprns:minWeightminimum weightprns:numberOfAuthorsnumber of authorsprns:numberOfConnectionsnumber of connectionsprns:numberOfPublicationsnumber of publicationsprns:personIdPerson IDprns:personInPrimaryPositionperson in primary positionprns:positionInDepartmentposition in departmentprns:positionInDivisionposition in divisionprns:predicateNodepredicate nodeprns:publicationDatepublication dateprns:sortOrdersort orderprns:uniquenessWeightuniqueness weightprns:yearyearAcademic ArticleArticleDocumentbibo:pmidPubMed Identifiervivo:authorRankauthor rank in publicationAuthorshipDepartmentDivisionvivo:hasSubjectAreahas subject areavivo:hrJobTitleHR job titleInformation Resourcevivo:informationResourceInAuthorshipauthorsvivo:linkedAuthorlinked authorvivo:linkedInformationResourcelinked information resourcePositionvivo:positionInOrganizationposition in organizationvivo:preferredTitlepreferred titlerdf:predicatepredicaterdf:typetyperdfs:labellabelConceptAgentfoaf:firstNamefirst namefoaf:lastNamelast nameOrganizationPersonD004311Procedures1165030.892584Double-Blind MethodD010698Disorders11620.96125Phobic DisordersD016896Concepts & Ideas36434750.519249Treatment OutcomeD014151Chemicals & DrugsPhysiology9380.97716Anti-Anxiety Agentstrue1ProfessorProfessorPsychiatryMarkPollackMark Pollack41.87724600000000-87.66843480000000349127Pollack, MarkProfessorD003511Chemicals & Drugs3180.985843CyclohexanolsAuthorship 433114Professor0.4917660.4917661authors10.2516has subject areaD008875Concepts & IdeasLiving Beings48498180.3737Middle AgedD002998Chemicals & Drugs6290.98462ClonazepamD000328Living Beings51785940.393502AdultD020280Chemicals & Drugs4190.988959SertralineD008297Physiology565156330.299056MaleD005260Physiology580162050.293542FemaleD012720Concepts & Ideas23911110.709158Severity of Illness IndexRush University, Rush Medical CollegeD004334Concepts & Ideas842230.947675Drug Administration ScheduleD006801Living Beings644293510.211905HumansD0000694703170.99666Venlafaxine HydrochlorideD004359Procedures902410.940349Drug Therapy, Combination